 |
|
HOME » CORPORATE: MANAGEMENT TEAM

MANAGEMENT TEAM
PAUL BRENNAN
Chief Executive Officer
Paul Brennan was appointed as the
Company's Chief Executive Officer on October 20, 2009. Since May 2009 Mr.
Brennan has been a Principal at Pacific BioPartners, a consulting company
focusing on supporting Biotech companies, including MIGENIX, with general
management and business development expertise. From August 2008 to April
2009 Mr Brennan was the CEO and a Board Member of Altair Therapeutics an
emerging biopharmaceutical company based in San Diego and focused on
developing inhaled therapeutics for respiratory diseases. In January 2007,
Mr Brennan joined Aspreva Pharmaceuticals as Senior Vice President, Business
Development, and was involved in the sale of the company to the Galenica
Corporation for $920 million. Between 2002 and 2007 Mr Brennan worked for
AnorMED, and held various positions in Business Development, Marketing and
General Management. Mr Brennan was a Board Member and was Acting-President
of AnorMED when it was sold to the Genzyme Corporation for $590 million.
Prior to joining AnorMED Mr Brennan worked for AstraZeneca in a number of
management positions in Business Development and Regulatory Affairs based in
Canada, Sweden and the UK. Mr Brennan has a M.Sc and B. Sc from Queen's
University in Kingston.
BRUCE SCHMIDT
President and Chief Financial
Officer (Interim)
Bruce Schmidt was appointed as
the Company's President and Chief Executive Officer (interim) in August 2008
and provides those services through his management company, RJS Management
Ltd. Mr. Schmidt ceased to be the Company’s Chief Executive Officer
effective October 20, 2009 with the appointment of Mr. Brennan. From 1993 to
2000, Mr. Schmidt was a founder and Chief Executive Officer of a University
of British Columbia spin-off biotechnology company focused on novel
compounds for the treatment of various cancers and neurological disorders.
In 2000, Mr. Schmidt helped found Genome British Columbia, a life-sciences
research institute with the objective of building world class genomics
capabilities in Canada. Mr. Schmidt has also served as a director for a
number of high-tech and biotech companies in Canada. Mr. Schmidt is
currently a director of GreenAngel Energy Corp. and En2Go International
Ltd. Mr. Schmidt is a past-director of the Canadian Healthcare Licensing
Association, past-Chair of the B.C. Nanotechnology Alliance and past-Chair
of Life Sciences British Columbia (formerly BCBiotech).
|